“United by Research”: HICCC Honors National Cancer Research Month
This May, the Herbert Irving Comprehensive Cancer Center (HICCC) joins the American Association for Cancer Research (AACR) and cancer centers across the country in celebrating National Cancer Research Month. With the theme “United by Cancer Research,” National Cancer Research Month highlights the importance and impact of cancer research, from discoveries made in the lab to clinical trials providing life-saving research to people with cancer. Thanks to decades of progress, approximately 18.6 million people in the United States, and millions more around the world, are living with, through, and beyond their disease.
Advancing Cancer Research at Columbia
See how Columbia researchers are leading the way in the discovery and design of innovative cancer therapies to improve the quality of life for all those affected—in our region and throughout the world.
| From Idea to Impact: How Pilot Funding Fuels Cancer Discovery - Early-stage, strategic investments help researchers test bold ideas, creating momentum and new directions in cancer research. |
| Jack’s Story: Clinical Trial Brings Comprehensive Care - After joining an innovative clinical trial for his stage IV kidney cancer, Jack was amazed by the care he received - and the lifesaving result that followed. |
The Frontier of “Living Drugs” - From an unconventional vision for fighting cancer to a celebrated candidate for curing lupus, CAR-T cell therapy development is entering a new chapter with Michel Sadelain's arrival at Columbia.
Ironing Out Cancer - Columbia researchers have discovered the natural mechanism behind a type of cell death called ferroptosis - solving a longstanding puzzle in cell biology.
Turning ‘Unknown’ Cancer Mutations into Personalized Treatment Strategies - A new computational framework developed by Columbia researchers offers a new way to classify hundreds of thousands of previously uninterpretable cancer mutations.
Targeting KRAS: Promising New Therapy for Hard-to-Treat Lung Cancer Subtype - Zoldonrasib is a new drug designed for a KRAS mutation that currently has no approved treatment. After strong early responses, a global trial at the HICCC is underway with FDA Breakthrough status.
Focused Ultrasound Passes First Test in Treatment of Brain Cancer in Children - Columbia researchers show for the first time that focused ultrasound can safely open the blood-brain barrier in children, enhancing delivery of chemotherapy to tumors.